MedPredict Market Research

Home About Us Products & Services Therapeutic Areas Contact Us

LOGIN
User ID:
Password:
forgot id/password Register

	For Pharma and Biotech Decision-Makers	LATEST PUBLICATIONS

One of your key challenges is to stay on top of the latest activities in your target therapeutic areas. What’s happening with competitive compounds in the pipeline? What are their indications and marketing claims likely to be? How are trends in clinical practice evolving, and how will that affect your current and future business?

MedPredict delivers the insights that will drive your strategic decision-making, but without the big price tag and long lead-time required to conduct your own thought leader interviews or market research. We deliver a wide range of syndicated reports that are ready to download today, so you can act on the information right away. And if you don't see what you need in our syndicated reports database, we would be happy to provide you with a customized proposal for proprietary research.

Browse our site to see how MedPredict can provide the thought leader insight you need to make breakthrough strategic decisions.

Reports Coming Soon...

Alzheimer's Disease -- Post-ICAD

Psoriasis

Osteoporosis -- Post-ASBMR

Antithrombotics/Antiplatelets -- Post-ASH

Respiratory -- Post-ERS

Upcoming Events...

Visit our booth (#15) at the upcoming Pharma CI Conference & Exhibition...Details below.

Alzheimer's Disease Post-ICAD Report There were many controversies emerging from ICAD. In this report, Panelists take sides and comment on the data and how they think it should be interpreted. Most importantly, each side lays out cogent arguments supporting their opinions and predictions, pro and con, for the pharmacotherapies and diagnostics in the AD pipeline. learn more >>

Breast Cancer The discussions in our post-ASCO report center around the following topics: Bone and brain disease in breast cancer patients, osteonecrosis of the jaw, antiresorptive approaches in metastatic and adjuvant breast cancer; Triple negative breast cancer; Best approaches for development of inhibitors of mTOR, IGF1R, EGFR, PARP-1, HSP90, Src, angiogenesis, FA2, hedgehog, vaccines; and more. learn more >>

Multiple Sclerosis This panel of 6 neurology thought leaders reviews the MS pipeline, including the significance of the PML cases seen in patients on natalizumab and rituximab, the effect on prescribing and development of new potent immunosurveillants. learn more >>

Anxiety & Depression This report focuses on a variety of clinical approaches designed to bring meaningful new benefits to the treatment of depression and anxiety. In our last report we highlighted three key unmet needs – higher core efficacy, more durable remissions and lower side effects. In this report the Panel identifies the characteristics that next-generation therapeutics will need to go beyond those benefits and deliver enhanced cognition, reduced anhedonia, and relief from pain and fatigue. learn more >>